JP2015524849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524849A5 JP2015524849A5 JP2015527641A JP2015527641A JP2015524849A5 JP 2015524849 A5 JP2015524849 A5 JP 2015524849A5 JP 2015527641 A JP2015527641 A JP 2015527641A JP 2015527641 A JP2015527641 A JP 2015527641A JP 2015524849 A5 JP2015524849 A5 JP 2015524849A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- isolated
- disease
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 22
- 210000001808 exosome Anatomy 0.000 claims description 19
- 208000016192 Demyelinating disease Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 108091034054 MiR-138 Proteins 0.000 claims description 5
- 108091030496 miR-138 stem-loop Proteins 0.000 claims description 5
- 108091063841 miR-219 stem-loop Proteins 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000006999 cognitive decline Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 108091025686 miR-199a stem-loop Proteins 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683596P | 2012-08-15 | 2012-08-15 | |
| US61/683,596 | 2012-08-15 | ||
| PCT/US2013/055187 WO2014028763A1 (en) | 2012-08-15 | 2013-08-15 | Exosome-based therapeutics against neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524849A JP2015524849A (ja) | 2015-08-27 |
| JP2015524849A5 true JP2015524849A5 (cg-RX-API-DMAC7.html) | 2016-09-29 |
Family
ID=50101510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527641A Pending JP2015524849A (ja) | 2012-08-15 | 2013-08-15 | 神経変性疾患に対するエキソソームに基づく治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10231997B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2885414B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015524849A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013302526B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2882248A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014028763A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| JP2015524849A (ja) | 2012-08-15 | 2015-08-27 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 神経変性疾患に対するエキソソームに基づく治療法 |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2926092A1 (en) * | 2013-10-24 | 2015-04-30 | Nanosomix, Inc. | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| DK3145493T3 (da) * | 2014-05-18 | 2022-10-31 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende exosomer |
| US20170184613A1 (en) * | 2014-05-23 | 2017-06-29 | Georgetown University | Exosome and lipid biomarkers for memory loss |
| KR101766373B1 (ko) * | 2015-01-05 | 2017-08-09 | 권영아 | 루테리온을 이용한 암세포의 텔로머라아제 억제방법 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| JP7075594B2 (ja) * | 2015-11-18 | 2022-05-26 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | 神経細胞の細胞外小胞 |
| WO2017087685A1 (en) | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| WO2017124000A1 (en) | 2016-01-14 | 2017-07-20 | The Regents Of The University Of California | 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids |
| AU2017227790B2 (en) | 2016-03-02 | 2023-03-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Matrix bound nanovesicles and their use |
| WO2017152035A1 (en) * | 2016-03-03 | 2017-09-08 | Henry Ford Health System | 3-d collagen scaffold-generated exosomes and uses thereof |
| WO2018035204A1 (en) * | 2016-08-16 | 2018-02-22 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| US20210290556A1 (en) * | 2016-08-22 | 2021-09-23 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| WO2018071681A1 (en) | 2016-10-13 | 2018-04-19 | Vbc Holdings Llc | Cancer stem cell exosomes |
| KR20190109389A (ko) | 2016-11-03 | 2019-09-25 | 엑소스템 바이오텍 리미티드 | 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도 |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| ES2912270T3 (es) * | 2016-11-23 | 2022-05-25 | Mayo Found Medical Education & Res | Transporte de productos biológicos por medio de partículas |
| WO2018132728A1 (en) * | 2017-01-12 | 2018-07-19 | Duke University | Compositions and methods for the treatment of demyelinating conditions |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| CA3058782A1 (en) | 2017-04-03 | 2018-10-11 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| US11672849B2 (en) * | 2017-05-10 | 2023-06-13 | University Of Louisville Research Foundation, Inc. | Method of inhibiting lung or breast cancer growth with engineered embryonic stem-cell derived exosomes compositions |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CN108103026B (zh) * | 2017-12-05 | 2020-12-22 | 四川省肿瘤医院 | 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法 |
| CN107988153B (zh) * | 2017-12-15 | 2021-05-18 | 英科博雅生命科技有限公司 | 人脐带血间充质干细胞源分离外泌体的方法和使用的试剂 |
| US12017066B2 (en) | 2018-01-05 | 2024-06-25 | Mayo Foundation For Medical Education And Research | Modulation of extracellular vesicles with electrical stimulation |
| JP7538044B2 (ja) | 2018-04-30 | 2024-08-21 | ザ チルドレンズ メディカル センター コーポレーション | 間葉系間質細胞エキソソームおよびそれらの使用 |
| US11278575B2 (en) | 2018-07-12 | 2022-03-22 | Duke University | Compositions and methods for the treatment of demyelinating conditions |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020072744A1 (en) * | 2018-10-04 | 2020-04-09 | Synaptec Network, Inc. | Systems and methods for delivering exosomes through the blood-brain barrier |
| US20220133908A1 (en) | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| CA3142487A1 (en) * | 2019-06-04 | 2020-12-10 | Thomas Jefferson University | Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis |
| JP7372518B2 (ja) * | 2019-06-27 | 2023-11-01 | 国立大学法人山口大学 | 骨髄由来間葉系幹細胞の培養方法 |
| US20220241325A1 (en) * | 2019-07-26 | 2022-08-04 | Mayo Foundation For Medical Education And Research | Antioxidant and antiviral compositions and methods |
| CN111117964B (zh) * | 2019-07-30 | 2020-12-01 | 段海峰 | 一种肿瘤来源外泌体及其制备方法和用途 |
| TR201911667A2 (tr) | 2019-08-01 | 2021-02-22 | Univ Yeditepe | Hücrelerde oluşan protein birikintilerinden kaynaklanan hastalıkların tedavisi için kullanılan bitki eksozomları. |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| WO2021076973A1 (en) * | 2019-10-16 | 2021-04-22 | The Johns Hopkins University | Extracellular vesicle-based agents and methods for the treatment of neuropathic disorders |
| CN112972702A (zh) * | 2019-12-17 | 2021-06-18 | 南京大学 | 用于治疗耐药菌感染的外泌体制剂 |
| PH12022551608A1 (en) * | 2019-12-31 | 2023-10-16 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| WO2021154888A1 (en) * | 2020-01-27 | 2021-08-05 | Mantra Bio. Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
| US20230314412A1 (en) * | 2020-03-21 | 2023-10-05 | Florica Therapeutics, Inc. | Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases |
| CN111876388A (zh) * | 2020-07-24 | 2020-11-03 | 赛瑞诚(苏州)生物科技有限公司 | 一种骨和骨组织靶向外泌体及其制备方法和应用 |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| WO2022204045A1 (en) * | 2021-03-22 | 2022-09-29 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo |
| WO2023283218A2 (en) * | 2021-07-07 | 2023-01-12 | University Of Florida Research Foundation, Incorporated | Light-induced cellular production of immune functional extracellular vesicles |
| CN116440168A (zh) * | 2022-01-06 | 2023-07-18 | 南京大学 | 一种生物制品及其制备方法和其在制备抗衰延寿产品中的应用 |
| CN115006427A (zh) * | 2022-05-31 | 2022-09-06 | 尧舜泽生物医药(南京)有限公司 | 骨髓间充质干细胞外泌体在治疗帕金森病中的应用 |
| CN120712096A (zh) * | 2022-11-23 | 2025-09-26 | ExoMed私人有限公司 | 使用源自幼小哺乳动物的细胞外囊泡预防或治疗年龄相关病状的方法 |
| WO2024186630A1 (en) * | 2023-03-03 | 2024-09-12 | Henry Ford Health System | Use of extracellular vesicles for the treatment of cancer |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US7689196B2 (en) | 2002-06-26 | 2010-03-30 | Qualcomm Incorporated | Timer-based sleep for terminals in wireless communication systems |
| EP1713900A4 (en) * | 2004-01-27 | 2009-06-17 | Compugen Ltd | METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES |
| JP5697297B2 (ja) * | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| CA2676113C (en) * | 2007-07-25 | 2014-07-08 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| WO2009023517A2 (en) * | 2007-08-10 | 2009-02-19 | Wayne State University | Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system |
| EP2254586B1 (en) * | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| WO2013016223A2 (en) | 2011-07-22 | 2013-01-31 | The University Of Chicago | Treatments for migraine and related disorders |
| JP2015524849A (ja) | 2012-08-15 | 2015-08-27 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 神経変性疾患に対するエキソソームに基づく治療法 |
-
2013
- 2013-08-15 JP JP2015527641A patent/JP2015524849A/ja active Pending
- 2013-08-15 EP EP13829748.6A patent/EP2885414B1/en active Active
- 2013-08-15 CA CA2882248A patent/CA2882248A1/en not_active Abandoned
- 2013-08-15 AU AU2013302526A patent/AU2013302526B2/en active Active
- 2013-08-15 WO PCT/US2013/055187 patent/WO2014028763A1/en not_active Ceased
- 2013-08-15 US US14/420,680 patent/US10231997B2/en active Active
-
2019
- 2019-01-28 US US16/259,563 patent/US11369634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524849A5 (cg-RX-API-DMAC7.html) | ||
| Yuan et al. | Biogenesis, composition and potential therapeutic applications of mesenchymal stem cells derived exosomes in various diseases | |
| JP2025108487A (ja) | 幹細胞の培養及び治療のための培地、方法、細胞、及び分泌因子 | |
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| NZ628328A (en) | Rna formulation for immunotherapy | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP2019504105A5 (cg-RX-API-DMAC7.html) | ||
| NZ591326A (en) | An extended release pharmaceutical composition of entacapone or salts thereof | |
| JP2015512418A5 (cg-RX-API-DMAC7.html) | ||
| NZ773177A (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
| HK1205156A1 (en) | Cyclodextrin-based polymers for therapeutic delivery | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| JP2016508123A5 (cg-RX-API-DMAC7.html) | ||
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| Wang et al. | The potential therapeutic role of the HMGB1-TLR pathway in epilepsy | |
| RU2021135194A (ru) | Способы и аппараты для подготовки клеточных популяций для клеточной терапии | |
| MX376783B (es) | Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. | |
| JP2018522880A5 (cg-RX-API-DMAC7.html) | ||
| CN104173363A (zh) | 一种腺苷化合物在制备防治应激障碍药物中的用途 | |
| EP4365289A3 (en) | Rna interference delivery formulation and methods for malignant tumors |